CTO: Trials vs. Real-World

Percutaneous coronary intervention of chronic total occlusions (CTO) is currently indicated for symptom improvement, as studies have inadequate randomization of data which hinders the assessment of hard outcomes. However, patient inclusion in randomized controlled trials has been challenging, especially for highly symptomatic and higher risk patients. This causes a selection bias in randomized studies on CTOs.

CTO: Trials vs Mundo Real

The purpose of this meta-analysis was to evaluate the differences between patients with CTOs in the real world vs. those who were included in randomized studies.

Outcomes were evaluated in terms of procedural success, in-hospital mortality, acute myocardial infarction (AMI), major cardiovascular events (MACE), and cardiac tamponade. Procedural success was defined as technical success (<30% residual stenosis with TIMI 3 flow) without MACE.

In this study, the analysis included 6 randomized controlled studies comparing CTA to CTO vs. medical treatment (N = 1047), 10 CTO-dedicated registries (N = 76,467), and 5 national registries (N = 110,349). Most patients in the randomized studies were men and had a trend of lower comorbidities such as diabetes, hypertension, peripheral artery disease, prior AMI, prior CTA, and prior myocardial revascularization surgery. In addition, these patients underwent procedures with longer fluoroscopy time and greater use of contrast material.

Procedural success was significantly lower in the national registries compared with the randomized studies (63.9% vs. 84.5%, relative difference = 24.4%). However, randomized studies had a higher risk of in-hospital events, including death (1.3% vs. 0.6%, relative difference = 52.3%), MACE (7.9% vs. 1.5%, relative difference = 81.0%), AMI (5.9% vs. 1.0%, relative difference = 83.1%), and cardiac tamponade (0.9% vs. 0.3%, relative difference = 66.7%).

Read also: Longitudinal Deformation of a Stent with the POT Technique.

When comparing patients from randomized studies vs. CTO-dedicated registries, patients included in the studies had shorter CTOs and low J-CTO scores (2.0-1.1 vs. 2.3-1.2, relative difference = 13.0%). Although procedural success was similar between both groups (84.5% vs. 81.4%), patients included in the studies presented a higher risk of in-hospital events (death, MACE, AMI, and cardiac tamponade).

Conclusion

Patients included in the randomized studies had less risk profile and less injury complexity than real-world registries. Current evidence from randomized controlled studies may not be representative of real-world patients and should be interpreted with this limitation. Procedures performed by surgeons specialized in CTOs have significantly more success and fewer complications than those performed by surgeons that are not specialized in CTOs.

Dr. Andrés Rodríguez

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Comparative Analysis of Patient Characteristics in Chronic Total Occlusion Revascularization Studies Trials vs Real-World Registries.

Reference: Michael Megaly, MD  et al J Am Coll Cardiol Intv 2022;15:1441–1449.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....